D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Earnings Guidance for the Full Year Ending December 31, 2020
May 15, 2020 at 03:00 am EDT
Share
D. Western Therapeutics Institute, Inc. announced consolidated earnings results for the first quarter ended March 31, 2020. For the period, the company reported net sales of JPY 74 million against JPY 275 million a year ago. Operating loss was JPY 50 million against profit of JPY 145 million a year ago. Net loss attributable to equities of parent was JPY 53 million or JPY 1.66 per basic share against profit of JPY 143.5 million or JPY 5.81 per basic share a year ago.
The company provided earnings guidance for the full year ending December 31, 2020. For the year, the company expects to report net sales of JPY 310 million, operating loss of JPY 390 million and net loss attributable to owners of the parent was JPY 340 million or JPY 12.94 per share.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Earnings Guidance for the Full Year Ending December 31, 2020
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
